Review article · 2022 · Open access

Akkermansia muciniphila: The state of the art, 18 years after its first discovery

Rim Iwaza, Reham Magdy Wasfy, Grégory Dubourg, Didier Raoult, Jean‐Christophe Lagier

Frontiers in Gastroenterology, 1, 1024393 · Published 25 October 2022 · DOI 10.3389/fgstr.2022.1024393

Open full textCite this paper

In brief

“Akkermansia muciniphila: The state of the art, 18 years after its first discovery” is a 2022 review article by Rim Iwaza and 4 co-authors, published in Frontiers in Gastroenterology. OpenAlex counts 38 citations as of 21 November 2026, which puts it in the top 3% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Gastroenterology.

Citations
38
Most cited in
2026 (12)
Field-weighted impact
0.62
References
171
Authors
5

Abstract

Akkermansia muciniphila (A. muciniphila) is an anaerobic, Gram negative and mucin-degrading bacterium of the phylum Verrucomicrobia isolated in 2004 from human feces. Although it is a common resident in the human intestinal tract, it has also been detected in other anatomical sites. Genomic studies have revealed that A. muciniphila can be divided into different phylogroups with distinct metabolic properties. There is growing evidence regarding its beneficial impact on human health. Indeed, A. muciniphila is considered as a promising next-generation probiotic for treating cancer and metabolic disorders. The large-scale production of A. muciniphila is, therefore, a challenge. Beside mucin-based medium, other culture strategies have enabled its isolation. The administration of both live and pasteurized forms of A. muciniphila has shown to be promising in animal models. Alternatively, the administration of various prebiotics has also been assessed for enhancing its abundance in the human gut. Future prospects include human clinical trials, some of which are currently ongoing. This paper provides an overview of what is currently known about A. muciniphila’s phenotypical and genotypic traits, as well as its culture techniques and its connections to a number of human diseases and its potential application as an effective next generation probiotic.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Iwaza, R., Wasfy, R. M., Dubourg, G., Raoult, D., & Lagier, J. (2022). Akkermansia muciniphila: The state of the art, 18 years after its first discovery. Frontiers in Gastroenterology, 1, 1024393. https://doi.org/10.3389/fgstr.2022.1024393

MLA 9

Iwaza, Rim, et al. “Akkermansia muciniphila: The state of the art, 18 years after its first discovery.” Frontiers in Gastroenterology, vol. 1, 2022, p. 1024393. https://doi.org/10.3389/fgstr.2022.1024393.

Chicago

Iwaza, Rim, Reham Magdy Wasfy, Grégory Dubourg, Didier Raoult, and Jean‐Christophe Lagier. 2022. “Akkermansia muciniphila: The state of the art, 18 years after its first discovery.” Frontiers in Gastroenterology 1: 1024393. https://doi.org/10.3389/fgstr.2022.1024393.

Harvard

Iwaza, R. et al. (2022) ‘Akkermansia muciniphila: The state of the art, 18 years after its first discovery’, Frontiers in Gastroenterology, 1, p. 1024393. doi:10.3389/fgstr.2022.1024393.

IEEE

R. Iwaza, R. M. Wasfy, G. Dubourg, D. Raoult, and J. Lagier, “Akkermansia muciniphila: The state of the art, 18 years after its first discovery,” Frontiers in Gastroenterology, vol. 1, p. 1024393, 2022, doi: 10.3389/fgstr.2022.1024393.

BibTeX

@article{iwaza2022akkermansia,
  title     = {{Akkermansia muciniphila: The state of the art, 18 years after its first discovery}},
  author    = {Iwaza, Rim and Wasfy, Reham Magdy and Dubourg, Grégory and Raoult, Didier and Lagier, Jean‐Christophe},
  journal   = {Frontiers in Gastroenterology},
  year      = {2022},
  volume    = {1},
  pages     = {1024393},
  doi       = {10.3389/fgstr.2022.1024393},
  url       = {https://doi.org/10.3389/fgstr.2022.1024393}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202355
20241010
20251111
20261212

Its field-weighted citation impact is 0.62: it has been cited 0.62 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health

  • Akkermansia muciniphila
  • Verrucomicrobia
  • mucin-degrading bacteria
  • human gut microbiome
  • probiotics
  • phylogenetic groups
  • prebiotics
  • cancer

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Iwaza, R., Wasfy, R. M., Dubourg, G., Raoult, D., & Lagier, J. (2022). Akkermansia muciniphila: The state of the art, 18 years after its first discovery. Frontiers in Gastroenterology, 1, 1024393. https://doi.org/10.3389/fgstr.2022.1024393

How many times has this paper been cited?

38 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Gastroenterology: sign in and open the full text from this page.

Who wrote this paper?

Rim Iwaza, Reham Magdy Wasfy, Grégory Dubourg, Didier Raoult, Jean‐Christophe Lagier.

What is the DOI of this paper?

10.3389/fgstr.2022.1024393, permanently at https://doi.org/10.3389/fgstr.2022.1024393. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.